Neogenomics Stock

Neogenomics Forward P/E

The Forward P/E Ratio of Neogenomics (NEO) as of Jul 24, 2026 is -13.63. In the previous year, Forward P/E Ratio was -18.70 — a change of -27.12% (higher).

Forward P/E

-13.63

YoY

-27.12%

Last updated:

Forward P/E Ratio of Neogenomics is 2026 -13.63 . Forward P/E Ratio of Neogenomics was 2025 -18.70 . It decreases by -27.12% higher compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

Forward P/E Ratio of Neogenomics is -13.63 in 2026.

Access this data via the Eulerpool API

Valuation — Neogenomics

All Key Metrics — Neogenomics